Nanobiotix SA has landed Johnson & Johnson Inc. subsidiary Janssen Pharmaceutica NV as commercialization partner for NBTXR-3, a radioenhancer for boosting the effectiveness of standard radiotherapy, in a deal worth up to $1.86 billion for the initial indications. That headline figure covers current programs in head and neck cancers and lung cancers. There is the potential for Nanobiotix to earn up to $650 million more if Janssen decides to pursue up to five new indications that it will select, while for new indications that Nanobiotix selects to develop in alignment with Janssen, Nanobiotix will receive up to $220 million per program.